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The Adenomatous Polyposis Coli (APC) gene is
mutated in the majority of colorectal cancers
(CRCs). Loss of APC leads to constitutively active
WNT signaling, hyperproliferation, and tumorigen-
esis. Identification of pathways that facilitate tumor-
igenesis after APC loss is important for therapeutic
development. Here, we show that RAC1 is a critical
mediator of tumorigenesis after APC loss. We find
that RAC1 is required for expansion of the LGR5 in-
testinal stem cell (ISC) signature, progenitor hyper-
proliferation, and transformation. Mechanistically,
RAC1-driven ROS and NF-kB signaling mediate
these processes. Together, these data highlight
that ROS production and NF-kB activation triggered
by RAC1 are critical events in CRC initiation.
INTRODUCTION
Initiating mutations in colorectal cancer (CRC) most commonly
target the APC tumor suppressor gene (Kinzler and Vogelstein,
1996). APC is a negative regulator of WNT signaling that is
required to target b-catenin for proteosomal degradation. The
loss of the APC gene results in the accumulation of b-catenin
in the nucleus, subsequent activation of WNT transcriptional tar-
gets, and ultimately adenoma formation (Korinek et al., 1997;
Morin et al., 1997; Sansom et al., 2004). Normal intestinal ho-
meostasis is maintained by a number of intestinal stem cells
(ISCs). Recent experiments have shown the presence of a
cycling stem cell population marked by LGR5 along with a
longer-lived population that can repopulate the crypt after injury
(Barker et al., 2007; Buczacki et al., 2013). LGR5 expression
marks crypt columnar stem cells that have a readily identifiable
transcriptional profile termed the ISC signature. Genetic deletion
of Apc within LGR5 ISCs leads to rapid adenoma formation,
whereas deletion within more differentiated lineages leads to
poorly proliferative lesions that fail to progress without additional
oncogenic mutations (Schwitalla et al., 2013). Interestingly,although an established WNT target, LGR5 is only expressed
in a subset of APC-deficient tumor cells. This may be due to
LGR5 marking cells with the highest levels of WNT signaling or
to co-operation of multiple pathways in conferring the LGR5
ISC phenotype.
Our previous studies have shown that the WNT target gene
Myc is required for the phenotypes induced by Apc loss and
that reduced levels of MYC slows intestinal tumorigenesis (Athi-
neos and Sansom, 2010; Sansom et al., 2007). These studies set
a precedent that targeting the downstream effectors of WNT
signaling may be of therapeutic benefit in colorectal cancer. In
the case of MYC, although there is great interest in it as a thera-
peutic target (Soucek et al., 2008), in vivo inhibitors are still in
development. Therefore identification of other pathways down-
stream of Apc loss, in particular those highly active in LGR5
ISCs may provide candidates to target APC-deficient cells.
One candidate pathway is RAC signaling. RAC1 is a GTPase
that acts as a key signaling node modulating a diverse set
of cellular processes including proliferation, apoptosis, migra-
tion, and invasion. It influences a variety of signaling pathways
including MTOR, NF-kB, JNK, and reactive oxygen species
(ROS) production (Ellenbroek and Collard, 2007). RAC1 cycles
between an inactive GDP and active GTP-bound state and
is controlled by guanine nucleotide exchange factors (GEFs)
(which activate RAC1) and GTPase-activating proteins (which
inactivate RAC1). We previously identified MYC-dependent
upregulation of a number of RACGEFs after Apc loss, and
RACGEFs are commonly overexpressed during tumor pro-
gression (Lindsay et al., 2011; Sansom et al., 2007). RAC1-acti-
vating mutations have also been discovered in melanoma and a
constitutively active RAC1 isoform termed RAC1B identified in
colon and lung tumor samples can promote lung tumorigenesis
(Hodis et al., 2012; Krauthammer et al., 2012; Zhou et al., 2013).
RAC1 is also required for KRAS-mediated tumorigenesis in skin
and the lung, but the mechanism of how RAC1 loss suppresses
tumorigenesis is still unclear (Kissil et al., 2007; Samuel et al.,
2011). Therefore, it is important to elucidate how RAC1 drives
tumorigenesis.
Two studies suggest that RAC1 is required for nuclear locali-
zation of b-catenin and WNT signaling (Phelps et al., 2009; Wu
et al., 2008). First, Wu and colleagues demonstrated that RAC1
is required for b-catenin nuclear localization in the developingCell Stem Cell 12, 761–773, June 6, 2013 ª2013 Elsevier Inc. 761
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The Stem Cell Phenoytpe of APC Loss Requires RAC1limb bud and the effects of its deletion phenocopy those of
b-catenin. As nuclear localization of b-catenin is a key event dur-
ing CRC initiation if this dependency remains once Apc is
deleted, it would suggest that RAC1 would be an excellent ther-
apeutic target. Additionally, Phelps and colleagues demon-
strated that in zebrafish, apc loss alone was insufficient to cause
nuclear localization of b-catenin (Phelps et al., 2009). Here the
consequence of apc loss was perturbed differentiation, which
was dependent on the transcriptional repressor Ctbp1. Addi-
tional activation of Kras was required for nuclear accumulation
of b-catenin and hyperproliferation after apc loss. The authors
proposed that RAC1 activation downstream of constitutive
Kras activity was the mechanism that allowed the nuclear accu-
mulation of b-catenin. These results are controversial as a
number of studies have shown that (1) b-catenin can be nuclear
localized in human adenomas without KRAS mutation (Obrador-
Hevia et al., 2010), (2) WNT target genes can be upregulated in
human adenomas without KRAS mutation (Sabates-Bellver
et al., 2007), and (3) murine studies have shown nuclear b-cate-
nin and WNT target gene upregulation in adenomas from the
ApcMin/+ mouse (Sansom et al., 2004; Segditsas et al., 2008).
Therefore, given this evidence for a role of RAC1 in WNT
signaling, we investigated the importance of RAC1 activation
after Apc deletion. We show that a number of RacGEFs and
Rac1b are upregulated after Apc deletion, which leads to
increased activity of RAC1. While Rac1 deletion did not stop
the nuclear accumulation of b-catenin and activation of the ma-
jority of the TCF/LEF targets, it attenuated hyperproliferation af-
ter Apc loss and subsequent tumorigenesis. Finally, we show
that this is due to RAC1-mediated control of ROS production
and NF-kB activation.
RESULTS
RAC1 Is Activated after Apc Loss
Previous microarray analysis revealed upregulation of several
RACGEFs after Apc loss (Sansom et al., 2007). We found signif-
icant overexpression of Vav3 and Tiam1 transcripts after Apc
loss in a MYC-dependent manner (as synchronous deletion of
Apc andMyc returned expression levels towild-type) (Figure 1A).
Chromatin immunoprecipitation (ChIP) revealed that MYC was
bound to the Tiam1 promoter, demonstrating it is a direct MYC
target (Figure S1A available online). Moreover, we observed
increased expression of Rac1b but not Rac1 (Figure 1A). To
investigate whether this led to increased RAC1 activation, we
performed immunohistochemistry (IHC) using an antibody raised
against RAC-GTP (Samuel et al., 2011). We observed increased,
specific positivity for RAC-GTP in APC-deficient tissue that was
dependent on MYC (Figure 1B). Pull-downs for active RAC1 in
wild-type and APC-deficient intestinal extracts confirmed these
results (Figure S1B). Levels of RAC1 protein and mRNA re-
mained unchanged (Figures 1A and S1C). To assess RAC activa-
tion in human CRC, we stained a TMA containing 50 normal and
650 primary CRC tumor cores for RAC-GTP (Figures 1C and
S1D) (Duncan et al., 2008; O’Dwyer et al., 2011). We found a sig-
nificant (p% 0.0001) increase in RAC-GTP staining intensity at all
tumor stages compared to normal tissue, indicating that RAC
activation is an early event in CRC.We also stained a commercial
TMA for RAC-GTP, TIAM1, VAV3, and MYC and found a signifi-762 Cell Stem Cell 12, 761–773, June 6, 2013 ª2013 Elsevier Inc.cant correlation between the expressions of these proteins (Fig-
ures 1D and S1E). These data are consistent with previous
studies suggesting that RAC1 expression (and presumably acti-
vation) is elevated in CRC (Espina et al., 2008). Therefore, our
data suggest that in mammalian cells, activation of RAC1 occurs
downstream of WNT activation.
Rac1 Deletion Inhibits Hyperproliferation and LGR5 ISC
Expansion after Apc Loss
To assess the functional significance of RAC1 activation after
Apc loss, we generated vil-Cre-ERT2 Apcfl/fl Rac1fl/fl (APC
Rac1) mice (el Marjou et al., 2004; Walmsley et al., 2003).
Four days after cre induction, we observed loss of both Rac1
and Rac1b mRNA and RAC1 protein (Figures 1A and S2A). In
contrast to induced vil-Cre-ERT2 Apcfl/fl mice (APC), the intes-
tines from APC Rac1 mice had smaller hyperproliferative crypts
with significantly reduced incorporation of BrdU (Figures 2A
and S2B). Acute deletion of Rac1 alone (vil-Cre-ERT2 Rac1fl/fl)
did not affect crypt size, proliferation, or ISC lineage-tracing ca-
pacity (Figures 2A and S2C), although increased apoptosis of
villi enterocytes and intestinal barrier breakdown was observed
at later time points (data not shown). This prevented later time
point analysis and ruling out of potential subtle homeostatic
effects over the longer term. The vil-Cre-ERT2 transgene also in-
duces recombination in the colonic epithelium and the RAC1-
dependent intestinal proliferation phenotype was recapitulated
in this tissue (Figure S2D). Thus, RAC1 is a critical component
in permitting crypt progenitor hyperproliferation after Apc
loss in the intestinal and colonic epithelia. Given previous
studies reporting that RAC1 is required for accumulation of nu-
clear b-catenin (Phelps et al., 2009; Wu et al., 2008), we pre-
dicted that this and downstream target gene activation should
be impaired in APC Rac1 intestines. However, IHC analysis
showed nuclear b-catenin in APC Rac1- (and APC-) deleted in-
testines (Figure 2B). Moreover, quantitative RT-PCR (qRT-PCR)
of selected TCF/LEF targets that are deregulated after Apc loss
were unchanged in APC Rac1 intestines (Figure S2E) (Sansom
et al., 2007). Thus, RAC1 is not required for b-catenin nuclear
localization and/or its functional activity in the absence of
APC. To delineate the mechanism, we compared global gene
expression changes between APC and APC Rac1 intestines
by microarray. Gene set enrichment analysis (GSEA) identified
a significant overlap between our data set and the ISC signa-
tures associated with LGR5+ or EPHB2 high ISCs (chi-square
test with Yates’s correction, LGR5 p < 0.0001, EPHB2 p =
0.001) (Barker et al., 2007; Merlos-Sua´rez et al., 2011; van
der Flier et al., 2009). We confirmed that the ISC signature
was upregulated after Apc loss and reverted back to wild-
type levels in APC Rac1 intestines using qRT-PCR (Figure 2C).
To visualize changes in the LGR5-expressing population, we
generated inducible vil-Cre-ERT2 WT, Rac1, APC, and APC
Rac1 mice carrying the Lgr5GFP-CREER transgene (Barker
et al., 2007). LGR5-GFP expression is restricted to the base
of the crypt in wild-type and RAC1-deficient mice by IHC (Fig-
ure S2F). After Apc loss, there is a significant increase in the
number of LGR5-GFP-positive cells that are suppressed in
APC Rac1 intestines (Figure 2D). Moreover, scoring the location
of LGR5-expressing cells revealed a striking expansion of the
stem cell ‘‘zone’’ that codeletion of Rac1 prevented (Figure 2E).
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Figure 1. RAC1 Activity Is Increased after Apc Loss
(A) qRT-PCR of Tiam1, Vav3, Rac1b, and Rac1 (error bars represent SD; *p < 0.05, **p < 0.01, ***p < 0.001; t test, n = 3).
(B) IHC for RAC-GTP in WT, APC, APC Myc, and Rac1 intestines. Red arrows indicate epithelial expression, and black arrows show immune cells in the villus
compartment with very high positivity.
(C) Histoscores of human CRC TMA cores stained for RAC-GTP (Mann Whitney).
(D) Table comparing levels of active RAC, TIAM1, VAV3, and MYC in human CRC samples. All experiments are 4 days after induction. Scale bars represent
100 mm. See also Figure S1.
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The Stem Cell Phenoytpe of APC Loss Requires RAC1This was confirmed using multiphoton microscopy on intestines
(Figures S2G and S2H). To investigate whether Rac1 deletion
suppressed the proliferative potential of all ISC populations,
we purified crypts from APC and APC Rac1 intestines and
cultured them ex vivo. Remarkably, while APC crypts formed
colonies, APC Rac1 crypts did not, suggesting that RAC1 is
required for the clonogenic capacity of all intestinal cell types
(Figure S2I). Therefore, RAC1 is required for two critical constit-uents of Apc loss, progenitor hyperproliferation and LGR5 ISC
expansion.
Generation of ROS by RAC1 Allows LGR5 ISC Signature
Expansion upon Apc Loss
As RAC1 integrates many pathways, a plethora of downstream
effectors could account for the phenotype that we observed.
One critical cellular process requiring RAC1 is the generation ofCell Stem Cell 12, 761–773, June 6, 2013 ª2013 Elsevier Inc. 763
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Figure 2. RAC1 Is Required for Hyperproliferation and LGR5 ISC Expansion after Apc Loss
(A) Quantification of BrdU IHC in WT, Rac1, APC, and APC Rac1 intestines (Mann Whitney, n = 4).
(B) b-catenin IHC on WT, Rac1, APC, and APC Rac1 intestines. Nuclear b-catenin is found throughout the crypt in APC and APC Rac1 tissue (black arrows).
Histoscoring identified a significant increase in nuclear positivity after Apc loss (p = 0.04, Mann Whitney, n = 3) that was unchanged in APC Rac1.
(C) qRT-PCR of three ISC markers (error bars represent SD; t test, n = 3, *p < 0.05, **p < 0.01).
(D) Quantification of LGR5-GFP+ cell numbers.
(E) Cumulative frequency scoring of LGR5-GFP cell position (error bars represent SEM). All experiments 4 days after induction. Scale bars represent 100 mm. See
also Figure S2 and Tables S1 and S2.
Cell Stem Cell
The Stem Cell Phenoytpe of APC Loss Requires RAC1ROS. RAC1 is a member of the superoxide-generating NADPH
oxidase complex, and RAC1B overexpression has been shown
to lead to ROS production (Bromberg et al., 1994; Radisky
et al., 2005). The generation of ROS by NADPH oxidase involves
the conversion of NADPH to NADP+ so its activity can be evalu-
ated by the ratio of these molecules. We observed a shift in the
NADP+/NADPH ratio in APC intestinal extracts compared to
WT, indicating increased complex activity that wasRAC1 depen-
dent (Figure S3A). To analyze ROS levels within the intestinal
epithelium, we stainedWT, Rac1, APC, and APCRac1 intestines
with the ROS-responsive dye dihydroethidium (DHE). We764 Cell Stem Cell 12, 761–773, June 6, 2013 ª2013 Elsevier Inc.observed a significant increase in staining intensity in APC but
not APC Rac1 intestines (Figures 3A and 3B). Thus, Apc loss
leads to increased ROS generation in the intestinal epithelium
via activation of the RAC1-containing NADPH oxidase complex.
Moreover, DHE staining indicated that in WT tissue ROS gener-
ation was particularly high at the crypt base (Figure 3A). Scoring
DHE fluorescence intensity based on crypt cell position showed
that ROS generation was highest at cell positions 1–3 (where
LGR5+ cells reside) and was absent in RAC1-deficient intestines
(Figure S3B). To confirm that LGR5+ cells have high levels of
ROS, we isolated intestinal epithelial cells from mice carrying
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Figure 3. RAC1 Is Required for ROS Production in the Intestine
(A) Dihydroethidium (DHE) staining of frozen sections from WT, Rac1, APC, and APC Rac1 intestines; DAPI counterstain.
(B) Quanitification of DHE staining (error bars represent SD; t test, n = 3, *p < 0.05, **p < 0.01).
(C) Representative fluorescence-activated cell sorting (FACS) plot of CellROX Deep Red-stained epithelial cells from an Lgr5GFP-CREER-expressing mouse.
(D) Quantification of CellROX Deep Red staining (error bars represent SEM; t test, n = 3, ***p < 0.001).
(E) Expression of Rac signaling components and control ISCmarkers in LGR5-GFP+ cells relative to LGR5-GFP cells (error bars represent SEM; t test, n = 3, *p <
0.05, **p < 0.01). See also Figure S3.
Cell Stem Cell
The Stem Cell Phenoytpe of APC Loss Requires RAC1the Lgr5GFP-CREER transgene (Barker et al., 2007), stained them
with the ROS-responsive dye CellROX Deep Red, and analyzed
them by flow cytometry. We found that LGR5-GFP-expressing
cells contained around 2-fold more ROS than the cell population
as a whole (Figures 3C, 3D, and S3C). As ROS generation at the
crypt base was Rac1 dependent (Figures 3A and S3B), we inves-
tigated the expression of Tiam1, Vav3, andRac1b in LGR5+ cells
sorted by qRT-PCR and found that all were significantly en-
riched, though Rac1 levels were unchanged (Figure 3E).
We hypothesized increased RAC1-driven ROS generation
may be a critical process in conferring the ISC/progenitor pheno-
types associated with Apc loss. We tested this hypothesis in twoways. First, we assessed whether reduction of intracellular ROS
levels through NAC treatment could recapitulate the phenotypes
associated with Rac1 deletion. Remarkably, treatment of APC-
deficient mice with NAC strongly suppressed overexpression
of the ISC signature genes (Lgr5, Olfm4, and Rgmb) (Figure 4A).
This suppression did not extend to non-ISC WNT target genes,
indicating that WNT signaling was not perturbed by this treat-
ment (Figure S4A). NAC treatment also significantly attenuated
proliferation in APC intestines (Figures 4B and S4B). Importantly,
NAC treatment had no effect on proliferation, number of LGR5-
GFP cells, or gross villus histology in WT mice (4 day and
8 week time points) (Figure 4B and data not shown). Second,Cell Stem Cell 12, 761–773, June 6, 2013 ª2013 Elsevier Inc. 765
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Figure 4. ROS Is Required for Expansion of the
ISC Signature
(A) qRT-PCR of three ISCmarkers (error bars represent
SD; t test, n = 3, *p < 0.05, **p < 0.01).
(B) Quantification of BrdU staining of intestinal crypts
fromWT, APC,WT+NAC, and APC+NACmice (Mann
Whitney, n = 4).
(C) qRT-PCR of three ISC markers, downregulated in
APC Rac1-deficient intestines (AR) and upregulated
upon treatment with paraquat (AR + PQ) (error bars
represent SD; t test, n = 3, *p < 0.05, ***p < 0.001).
APC + PQ has been removed for clarity and is included
in Figure S4C.
(D) Quantification of BrdU positivity (Mann Whitney,
n = 6). All experiments are 4 days after induction. Scale
bars represent 100 mm. See also Figure S4.
Cell Stem Cell
The Stem Cell Phenoytpe of APC Loss Requires RAC1we asked whether induction of ROS could rescue the reduced
ISC signature in APC Rac1 intestines. Systemic treatment with
the ROS-inducing compound paraquat led to increased expres-
sion of ISC marker genes in APC Rac1 intestines (Figures 4C
and S4C). In situ microscopy of APC Rac1 mice carrying the
Lgr5GFP-CREER transgene demonstrated a significant expansion
of the ISC zone upon paraquat treatment (Figure S4D). In WT
and APC-deficient mice treated with paraquat, the majority of
ISC markers were unaffected. We also observed a significant in-
crease in proliferation in the intestines of the three cohorts of
paraquat-treated mice (Figures 4D and S4E). Thus, induction
of ROS can induce proliferation and, in the absence of RAC1,
can partially compensate for its loss.
RAC1-Driven NF-kB Signaling Mediates LGR5
ISC/Progenitor Hyperproliferation
We have recently demonstrated a requirement for the NF-kB
transcription factor P65 in ISC expansion after b-catenin activa-
tion (Schwitalla et al., 2013). Given the remarkable overlap with
this study, we addressed whether NF-kB signaling is an impor-
tant mediator of LGR5 ISC/progenitor proliferation after Apc
loss. We observed a significant reduction of NF-kB signaling
components P65, IKKb, and acetyl-P65 in APC Rac1 compared
to APC-deficient intestines (Figures 5A, S5A, and S5B). Also, NF-
kB binding activity was perturbed in APC Rac1 compared to
APC intestinal extracts (Figure S5C). We also observed an in-766 Cell Stem Cell 12, 761–773, June 6, 2013 ª2013 Elsevier Inc.crease in p65 binding to the promoters of
Lgr5, Olfm4, and Rgmb after Apc loss that
was lost upon codeletion of Rac1 (Figures
5B and 5C). Thus, efficient activation of NF-
kB signaling in the intestine requires RAC1.
We next sought to functionally determine
whether constitutive NF-kB signaling can
compensate for Rac1 deletion. We crossed
APC Rac1 mice to mice carrying the
R26StopFLikk2ca allele (an inducible, consti-
tutively active Ikk2 allele from nowon referred
to as IKK) to generate APC Rac1 IKK mice
(Sasaki et al., 2006) (Figure 5D). This model
permits constitutive activation of NF-kB
signaling in the absence of RAC1. This was
sufficient to almost completely rescue theproliferation defect and partially rescue ISC marker expression
in APC Rac1 mice (Figures 5E, 5F, and S5D). Thus, NF-kB
signaling is an important downstream effector of RAC1 signaling
in promoting the phenotypes of Apc loss. We noted that neither
increased ROS nor NF-kB activation were able to completely
rescue the APCRac1 deletion phenotype. This is perhaps unsur-
prising given that we also observed effects on a number of other
pathways downstream of RAC1 signaling, such as STAT3 and
MTOR, which could impinge on the phenotypes of Apc loss
(Figure S5E).
Rac1 Deletion Prevents Transformation after Apc Loss
Our previous studies have shown that Apc deletion within ISCs
using Lgr5GFP-CREER leads to rapid tumorigenesis (Barker et al.,
2009). Given that Rac1 deletion prevents increased Lgr5 expres-
sion within Apc-deficient crypts, we hypothesized that this
would reduce the tumor-forming capacity of ISCs. To test this,
we generated control Lgr5GFP-CREER Apcfl/fl (Lgr5 APC) and
experimental Lgr5GFP-CREER Apcfl/fl Rac1fl/fl (Lgr5 APC Rac1)
mice. To induce recombination, we gave mice a daily injection
of tamoxifen for 4 days (a total of four injections). Most control
Lgr5 APC mice developed a lethal intestinal adenoma burden
by 20 days; however, none of the Lgr5 APC Rac1 did until
much later time points (Figure 6A). When they did succumb to
adenoma formation, all adenomas expressed Rac1, indicating
that they most likely arose from cells in which Rac1 deletion
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Figure 5. NF-kB Signaling after Apc Loss Requires RAC1
(A) P65 IHC shows decreased expression in APC Rac1 crypts.
(B) ChIP of P65 to the Lgr5, Olfm4, and Rgmb promoters and a control region (error bars represent SD; Mann Whitney, n = 3, p = 0.04).
(C) Control ChIP showing no binding to ISC promoters of a nonspecific IgG (error bars represent SD).
(D) Crossing strategy to generate Vil APC Rac1 IKK mice.
(E) Quantification of BrdU positivity (Mann Whitney, n = 4).
(F) qRT-PCR of three ISC markers showing increased expression in APC Rac1 mice after NF-kB activation (error bars represent SEM; t test, n = 3, *p < 0.05). All
experiments were performed 4 days after induction. Scale bars represent 100 mm. See also Figure S5.
Cell Stem Cell
The Stem Cell Phenoytpe of APC Loss Requires RAC1had not occurred (Figure S6A). Histological analysis revealed
that in contrast to the adenomas found in controls, Lgr5 APC
Rac1 mice developed numerous cystic structures and micro ad-
enomas (Figures 6B and 6E). These lesions phenotypically
resemble those that arise via Apc deletion outside the stem
cell zone (Barker et al., 2009) and had a very low proliferative in-
dex (Figure 6E). Despite high levels of nuclear b-catenin, they
had reduced levels of LGR5-GFP, suggesting that RAC1 activityis essential for tumor growth and the efficient expansion of LGR5
cells after Apc loss (Figures 6F, 6G, and S6B). LGR5 also marks
colonic stem cells, and deletion of Apc with Lgr5GFP-CREER leads
to formation of colonic adenomas (Barker et al., 2009). At the
time of sacrifice, few colonic adenomas were macroscopically
visible in either Lgr5 APC or Lgr5 APC Rac1 mice. However,
microscopic analysis uncovered numerous aberrant crypt foci
andmicro adenomas in the colons of Lgr5 APCmice that stainedCell Stem Cell 12, 761–773, June 6, 2013 ª2013 Elsevier Inc. 767
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Figure 6. RAC1 Is Required for Tumorigenesis Downstream of Apc Loss
(A) Compared to Lgr5 APC, Lgr5 APC Rac1 mice were strongly protected against tumorigenesis (Kaplan Meier, p < 0.0001, n = 15).
(B and C) Lgr5 APC mice developed adenomas (B, H&E) that were highly proliferative (C, BrdU).
(D and E) Lgr5 APC Rac1 mice predominantly developed small intestinal lesions or cysts (D, H&E) that were poorly proliferative (E, BrdU IHC, red arrows). BrdU
incorporation was higher in neighboring normal intestine (black arrows).
(F and G) GFP IHC showing high levels of Lgr5-GFP staining in Lgr5 APC adenomas (F) compared to Lgr5 APC Rac1 lesions (G).
(H) NAC treatment protected Lgr5 APC mice from intestinal tumorigenesis (Kaplan Meier, p = 0.001, n = 7).
(I) Tumor volume scores of allografts derived from 100 APC Kras and APC Kras Rac1-purified crypts (error bars represent SD; t test, n = 3, *p < 0.05, **p < 0.01).
(J) Quantification of FACS analysis demonstrating a significant reduction in LGR5-GFP positivity in tumors deficient in RAC1 (Mann-Whitney, nR 5). Scale bars
represent 200 mm. See also Figure S6.
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Figure 7. Model of RAC1-Mediated Control
of Intestinal Tumor Initiation
(A) Normal small intestinal crypt with different cell
populations outlined. LGR5 ISCs have high Wnt
signaling leading to high RAC1-ROS-NF-kB
pathway activation.
(B) Upon loss of Apc, RAC1-ROS-NF-kB pathway
activation is increased throughout the crypt,
permitting the expansion of the LGR5 ISC zone
and progenitor cell hyperproliferation. The acti-
vation of the RAC1-ROS-NF-kB pathway
throughout the crypt is critical for intestinal ade-
noma formation.
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We observed a significant reduction in the number of these le-
sions in the colons of Lgr5 APC Rac1 mice (Figure S6D), with
the majority of these mice (6/8) being tumor free. Thus, RAC1
is required for intestinal and colonic adenoma formation after
Apc loss. To test whether ROS production by RAC1 was also
important, we treated Lgr5 APCmice with NAC. This led to a sig-
nificant extension of tumor-free lifespan, further emphasizing the
role ROS plays in intestinal transformation (Figure 6H).
As CRC progresses, tumors accumulate additional mutations,
of which the activation of KRASG12D (Kras) is one of the most
common (Cancer Genome Atlas Network, 2012). Therefore, we
generated vil-Cre-ERT2 Apcfl/fl KrasG12D/+ (APC Kras) and
vil-Cre-ERT2 Apcfl/fl KrasG12D/+ Rac1fl/fl (APC Kras Rac1) mice.
Three days after induction, we purified crypts from these mice
and assessed their tumor formation capacity by injecting them
into nude mice. Strikingly, crypts from APC Kras intestines
were able to efficiently form tumors, whereas those from APC
Kras Rac1 animals did not (Figure 6I). In the two out of six casesCell Stem Cell 12, 761–in which delayed tumor formation
occurred from Apc Kras Rac1 crypts,
they were found to express Rac1, indi-
cating that these grew from rare crypts
that had not lost Rac1 (data not shown).
Together, these data strongly indicate
an essential role for RAC1 in intestinal ad-
enoma formation.
A recent study has demonstrated that
LGR5 marks a population of cancer
stem cells (CSCs) within mouse intestinal
adenomas (Schepers et al., 2012). As
RAC1 permits the proliferation of LGR5
ISCs after Apc loss, we asked whether
RAC1 is important for maintaining this
population in established tumors. Specif-
ically, we wanted to assess the impact of
deletion of Rac1 from the LGR5+ popula-
tion within adenomas. For this, we inter-
crossed mice carrying the Apc1322T allele
(Pollard et al., 2009) to Lgr5GFP-CREER
mice. To test recombination within tu-
mors, we aged Lgr5GFP-CREER Apc1322T
carrying the Rosa26-RFP reporter (Fig-
ure S6E) to 60 days, when mice havesmall tumors and induced recombination with tamoxifen. In
agreement with previously published work, we observed lineage
tracing within both wild-type epithelium and in adenomas, with
marked RFP-positive clones 3 weeks after induction in both (Fig-
ures S6F and S6G) (Schepers et al., 2012). Given that we were
able to induce recombination within adenomas, we aged
Lgr5GFP-CREER Apc1322T/+ Rac1fl/fl mice until they developed
signs of intestinal tumor burden (weight loss and anemia) and
induced recombination. Rac1 deletion significantly reduced the
number of LGR5-GFP-positive cellswithin the tumors (Figure 6J).
Moreover, the reduction in the number of LGR5-GFP-positive
cells was partially ablated by concurrent treatment of mice
with paraquat (Figure S6J). Thus, RAC1 is required for LGR5
maintenance in intestinal adenomas.
DISCUSSION
Here, we demonstrate a critical requirement for RAC1 in intesti-
nal transformation after Apc loss (Figure 7). In contrast to773, June 6, 2013 ª2013 Elsevier Inc. 769
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localization of b-catenin (Wu et al., 2008), we find that RAC1
acts downstream of constitutive WNT signaling to promote pro-
genitor cell proliferation and expansion of the LGR5 ISC popula-
tion. This may reflect a difference between the effects of WNT3A
stimulation andApc loss or may indicate a tissue-specific role for
RAC1 in b-catenin activation. We find that the dependence on
RAC1 for crypt hyperproliferation is translated to a tumor model
driven by Apc loss in LGR5 ISCs. These findings are striking as
other oncogenic mediators overexpressed after Apc loss,
including CYCLIN D1/D2, CD44, and MBD2, show much less
dramatic effects on crypt hyperproliferation or intestinal tumori-
genesis (Cole et al., 2010; Phesse et al., 2008; Zeilstra et al.,
2008). As RAC1 also suppresses proliferation of APC-deficient
cells after KRAS activation, we propose that it is essential for in-
testinal transformation.
Mechanistically, these phenotypes depend on RAC1-driven
production of ROS and NF-kB signaling. The role of ROS in
stem cell maintenance, cellular transformation, and CSC survival
appears to be context and tissue specific. In proliferative neural
stem cells, high levels of ROS regulate self-renewal by driving
PI3K/AKT signaling (Le Belle et al., 2011). Conversely, hemato-
poietic stem cells are sensitive to ROS levels and higher levels
limit their lifespan (Ito et al., 2006). Additionally, although produc-
tion of ROS via NOX1 upregulation is important for tumorigenesis
(Mitsushita et al., 2004), it has been reported that low levels of
ROS in CSCs help protect against radiotherapy-induced DNA
damage (Diehn et al., 2009). Our data suggest that after Apc
loss, LGR5 ISC/progenitor cell expansion is a critical process
during tumor initiation and is dependent on RAC1-driven ROS
production. Given that LGR5 ISCs maintain high levels of ROS
but are not dependent on it, we would hypothesize that
increased RAC1-ROS is critical for proliferation outside the
normal niche (Figure 7). RAC1 is also required for efficient
NF-kB signaling after Apc loss and, importantly, constitutive
activation of NF-kB in the absence of RAC1 partially rescued
the attenuated proliferation and ISC expansion phenotypes.
We also found that loss of RAC1 prevented p65 recruitment to
the promoters of ISC genes after Apc deletion. Our findings
are similar to those observed with p65 deletion after b-catenin
activation and suggest that after Apc loss, LGR5 ISC marker
genes require both b-catenin and p65 for full transcriptional acti-
vation (Schwitalla et al., 2013). RAC1 deficiency prevents this by
impairing NF-kB signaling, despite b-catenin nuclear accumula-
tion. The finding that ROS andNF-kBboth play important roles in
intestinal tumor initiation indicates a role for inflammation in this
process. Interestingly, a recent report outlines a role for inflam-
matory pathways in progenitor cell transformation in the foregut
(Liu et al., 2013). Thus, it is tempting to speculate that inflamma-
tory pathways are common mediators of stem/progenitor trans-
formation in multiple tissues.
The LGR5 ISC Signature and CRC
There is evidence of two different ISC populations (Barker et al.,
2007; Sangiorgi and Capecchi, 2008). One is highly proliferative,
located at the crypt base, and marked by LGR5 and the other is
relatively quiescent, label retaining, and expresses BMI1. The
focus of our study was on the proliferative LGR5 population
and we have not directly addressed whether RAC1 is required770 Cell Stem Cell 12, 761–773, June 6, 2013 ª2013 Elsevier Inc.for the transformation of BMI1 ISCs. A level of hierarchy between
ISC populations has been proposed. Under normal homeostatic
conditions, Lgr5 ISCs populate the intestine, but this population
can be depleted during times of intestinal stress. When this oc-
curs, Bmi1+ cells can produce Lgr5 ISCs and subsequently re-
populate the intestine (Tian et al., 2011). Interestingly, LGR5+
cells are also capable of generating the +4 population (Takeda
et al., 2011). This would argue against a strict hierarchical rela-
tionship between these populations and instead indicate that,
depending on various contexts, these ISC populations are inter-
changeable. The location, function, and plasticity of ISC popula-
tions are still subject to keen debate. Recent data has argued
that LGR5+ cells express markers of alternative ISC populations
and that immediate progenitor cells can regain stemness after
crypt damage (Mun˜oz et al., 2012; van Es et al., 2012). Perhaps
the simplest explanation is that LGR5+ ISCs are defined by their
crypt location and progenitor cells can regain ISC properties if
they enter the LGR5+ niche. Interestingly, we observed LGR5+
cells throughout the crypt after Apc loss, and this is dependent
on RAC1. Perhaps this is why RAC1 deletion and ROS inhibition
do not affect normal LGR5 ISC function, i.e., these factors are
critical for unrestrained proliferation outside the conventional
niche. It should be noted that despite being expanded after
Apc loss, the LGR5+ zone does not encompass all APC-defi-
cient cells and Apc deletion alone in LGR5 cells does not
lead to tumorigenesis. Thus, other mutations are probably
required to permit tumor formation from non-ISCs. We have
recently shown that activation of KRAS in concert with Apc
loss can induce dedifferentiation of villus enterocytes, leading
to tumor formation (Schwitalla et al., 2013). It would be inter-
esting to determine whether this process is RAC1 dependent.
Given the plasticity of the normal intestine, this may also relate
to how intestinal CSCs behave. If multiple CSC populations exist
and are interconvertible, then so-called stem cell therapies,
which specifically target a particular subpopulation of cells
would be unlikely to prove beneficial. As specific CSC popula-
tions are depleted, theymay be rapidly repopulated fromalterna-
tive ‘‘reserve’’ CSCs or progenitor populations. In this case, it
would be important to target both the CSCs and the proliferative
capacity of their descendants. In this regard, our data demon-
strate that RAC1 would be a particularly attractive candidate to
target these populations. Rac1 deletion suppressed both LGR5
ISC and progenitor hyperproliferation after deletion of Apc and
prevented tumor formation from LGR5+ cells. Importantly, delet-
ing Rac1 also suppressed proliferation of cells with activated
KRAS, thus expanding the potential range of tumors likely to
respond to RAC1 inhibition.
It is currently unclear whether LGR5 marks APC-deficient
ISCs. LGR5 marks a CSC population with tumor lineage-tracing
properties in murine adenomas and LGR5+ APC-deficient cells
have enhanced in vitro clonogenicity over LGR5 cells, but no
in vivo clonogenicity data are available (Schepers et al., 2012).
We have shown that LGR5 ISC expansion, in vitro clonogenicity
of APC crypts, and adenoma initiation are RAC1 dependent.
However, as sorted cells from adenomas do not transplant, we
were not able to determine their clonogenicity in vivo. Thus, we
cannot state categorically that RAC1 is required for APC-defi-
cient ISC function. Two recent studies have suggested very
different outcomes for CRC patients with high levels of LGR5
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expression of EphB receptors is closely correlated with LGR5
and other ISC markers in CRC, and those cancers with high
levels of these markers had a greater chance of relapse (Mer-
los-Sua´rez et al., 2011). In contrast, de Sousa E Melo and col-
leagues showed that while high levels of WNT signaling marks
CSC populations, those cancers in which the promoters of
LGR5 ISC markers were methylated were more likely to relapse
(de Sousa EMelo et al., 2011). Thus, it is not clear howwell LGR5
ISC marker expression defines CSCs in human tumors and how
this is linked to disease progression.
RAC1 as a Therapeutic Target?
We previously demonstrated that deletion of Myc was sufficient
to rescue all of the phenotypes of Apc loss. Although Rac1 dele-
tion did not completely recapitulate this, the comprehensive
suppression of tumor formation suggests that RAC1 is required
for transformation after Apc loss. As the majority of CRCs
contain APC mutations, this has been the focus of our study.
However, it would be interesting to determine whether Rac1
deletion also suppresses tumorigenesis in Apc-independent
murine CRC models (Heid et al., 2011; Li et al., 2012). Thus,
RAC1 may be a worthwhile therapeutic target during the early
stages of CRC. Interestingly, our data indicate that ROS and
NF-kB are two parallel pathways involved in promoting ISC/pro-
genitor proliferation downstream of RAC1. It should be noted
that activation of ROS or NF-kB was not sufficient to completely
rescue the phenotypes associated with Rac1 loss. This is impor-
tant in two respects. First, it demonstrates how robust the
requirement for RAC1 is to intestinal tumor formation. As a key
signaling node that integrates numerous downstream signaling
pathways, the potential therapeutic benefits of targeting it
should be high. Also, it would likely increase the range of tumors
that would be sensitive to its inhibition and reduce the scope for
drug resistance to develop. Second, it indicates that the RAC1
phenotype may also involve additional downstream pathways.
Indeed, activation of two other known target pathways of
RAC1, MTOR (Saci et al., 2011) and STAT3 (Simon et al.,
2000), were attenuated in intestines lacking APC and RAC1.
Both of these pathways have been shown to reduce though
not prevent polyposis in the ApcMin/+ mouse (Fujishita et al.,
2008; Musteanu et al., 2010). This may also explain why our
results do not perfectly phenocopy studies on any of the
RAC1-modified factors that we have examined. For example,
Ikkb deletion in an AOM/DSS-driven model does not completely
prevent tumorigenesis, whereas in our model, Rac1 deletion
does (Greten et al., 2004). Thus, the combined suppression of
a number of downstream effectors appears to have a much
more profound effect than deleting them individually. Thus, if effi-
cient RAC1 inhibitors remain elusive, it may be worth combining
inhibition of these downstream pathways. Another question that
remains is what happens at more advanced stages of CRC.
Would other mutations overcome the dependence of RAC1? It
is interesting to note that in the case of mTOR inhibition, addi-
tional KRAS mutation strongly suppresses the efficacy of rapa-
logs inmousemodels (Hung et al., 2010).We have demonstrated
that RAC1 is essential for the transformation of KRAS-mutated
crypts. Given previous reports that the transformation activity
of KRAS is dependent on RAC1 (Qiu et al., 1995), it seems likelythat RAC1 would remain an efficacious target even in the setting
of a KRAS mutation.
In summary, we have elucidated an important axis down-
stream of WNT/MYC signaling after Apc loss that is crucial
for LGR5 ISC/progenitor hyperproliferation and hence
tumorigenesis.
EXPERIMENTAL PROCEDURES
Mouse Experiments
All experiments were performed under the UK Home Office guidelines. The
background ofmicewere as follows:AhCre experiments were at least ten gen-
erations C57Bl6J, Apc1322T experiments were at least five generations
C57Bl6J, VilCre-ER experiments were performed on a mixed background
(50% C57Bl6J, 50% S129). The alleles used for this study were as follows:
c-Mycfl (Sansom et al., 2007), AhCre (Ireland et al., 2004), Apc580S (Sansom
et al., 2007), Rac1fl (Walmsley et al., 2003), VilCre-ER (el Marjou et al., 2004),
Lgr5-CreER (Barker et al., 2007), ROSA-tdRFP (Luche et al., 2007), and
R26StopFLikk2ca (Sasaki et al., 2006). Recombination by VilCreER was
induced with one intraperitoneal (i.p.) injection of 80 mg/kg tamoxifen per
day for 4 days. Analyses of VilCreER-induced mice were at day 4 after induc-
tion. GFP lineage tracing was performed by inducing recombination by AhCre
using a single i.p. injection of 80 mg/kg b-napthoflavone and analyzing GFP
expression 14 days later. Mice carrying the Lgr5-CreER transgene were given
one i.p. injection of 120 mg/kg tamoxifen, followed by one daily i.p. injection of
80 mg/kg tamoxifen for 3 days. This protocol was also used for inducing
recombination within preformed adenomas. For ROS inhibition, 0.5%N-acetyl
cysteine was added to drinking water for 1 week prior to Cre induction by
tamoxifen treatment. Treatment with paraquat was 10 mg/kg i.p. injection
every other day starting 2 days prior to tamoxifen induction.
Immunohistochemistry
Standard immunohistochemistry techniques were used throughout this study.
Primary antibodies and concentrations can be found in the Supplemental
Experimental Procedures. For each antibody, staining was performed on at
least threemice of each genotype and average staining intensity over the entire
tissue area was scored. Representative images are shown for each staining.
Microarray Analysis
We reverse transcribed 1 mg of total RNA isolated from intestinal tissue was to
cDNA and hybridized to Affymetrix Mouse Genome 430 2.0 microarrays. Cell
files of six samples were normalized and analyzed in Partek Genomics Suite
Software. RMA normalization and log2 transformation of the data was followed
by the differential gene expression analysis using ANOVA and post hoc linear
contrasts between all pairs of experimental conditions. Multiple test correc-
tions were performed for all calculated p values. Finally, the fold change values
were considered in ranking genes of interest. Enrichment analysis was per-
formed with chi-square test with Yates’s correction (Gold et al., 2007).
Additional methods are in the Supplemental Experimental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information for this article includes six figures, Supplemental
Experimental Procedures, and two tables and can be foundwith this article on-
line at http://dx.doi.org/10.1016/j.stem.2013.04.006.
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